BPC-157 and TB-500 stacking claims: what the evidence says

What did @elevii1 actually say?

The creator is talking about stacking two compounds they call "reda" and "mazzi" — shorthand for retatrutide and semaglutide (or possibly tirzepatide, given the nicknames are inconsistent in this space). Their core claim is that retatrutide "suppresses appetite, improves insulin sensitivity, and signals your body to burn more fat," and that pairing it with semaglutide works "at the mitochondrial level" to improve how cells produce and use energy. The conclusion: stacking them produces "crazy improvements in metabolism." That's the argument. Now let's look at whether any of it holds up.

To be clear about what's being discussed here: retatrutide is a triple agonist (GLP-1, GIP, glucagon receptors) currently in Phase 2/3 trials. It is not FDA-approved. Semaglutide is FDA-approved under brand names for diabetes and obesity. Neither has been studied together in a formal clinical stack trial.

Does the science back this up?

Partially, but the creator is significantly outrunning the evidence, especially on the mitochondrial claim. The appetite suppression and insulin sensitivity claims for GLP-1 receptor agonists are well-supported. The mitochondrial framing is where things get shaky.

On retatrutide's effects: a Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) showed participants losing up to 24% of body weight over 48 weeks, with improvements in fasting insulin and glucose. The glucagon receptor component does appear to increase energy expenditure, which is a real and documented mechanism. That's a point in the creator's favor.

On the mitochondrial claim for semaglutide: some preclinical research suggests GLP-1 agonists may influence mitochondrial function (Cen et al., 2021, Frontiers in Physiology), but this is mouse data and cell culture work. Translating that to "your cells now become better at burning fuel" in a human context is a leap. No peer-reviewed human trial has confirmed this as a primary mechanism of semaglutide's weight-loss effect.

What did they get wrong (or right)?

They got the basic pharmacology of retatrutide directionally right. They got the mitochondrial framing wrong, or at minimum, wildly oversimplified. And the stack claim has essentially no clinical backing.

What's correct: retatrutide's glucagon receptor agonism does increase resting energy expenditure compared to GLP-1-only agents. Nahra et al. (2021, Diabetes Care) showed glucagon receptor agonism increases basal metabolic rate in humans. That's real. Appetite suppression via GLP-1 pathways is also extensively documented.

What's wrong: the claim that adding semaglutide makes your body "better at burning fuel" in a mitochondrial sense is not established in human trials. More importantly, stacking two GLP-1-pathway compounds raises legitimate safety questions around additive side effects, particularly nausea, vomiting, and gastrointestinal distress, that the creator completely ignores. There is no published human data on this specific combination. Saying people see "crazy improvements" from this stack is anecdote dressed up as pharmacology.

What should you actually know?

Retatrutide is not approved for use. Any access to it right now is through compounded or gray-market sources, which carry real regulatory and quality risks. Semaglutide is approved, but stacking it with another GLP-pathway agent is not a validated clinical protocol.

The creator presents this as a straightforward metabolic upgrade. It isn't. GLP-1 and glucagon receptor agonists carry documented risks including pancreatitis, gallbladder disease, and for glucagon-heavy agents, potential effects on blood glucose that require monitoring (Nahra et al., 2021). Stacking compounds that work on overlapping receptor systems without clinical oversight is not "a game changer" in the way they imply. It's an experiment with an unknown risk profile.

If you're interested in GLP-1-based therapies, they do have meaningful evidence behind them. But that evidence is for specific approved agents at studied doses, not cobbled-together stacks promoted on TikTok. A licensed provider who can review your metabolic labs is the starting point, not a 60-second video.